Your browser doesn't support javascript.
loading
Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiotomy: a network meta-analysis.
Benenati, Stefano; Toma, Matteo; Canale, Claudia; Vergallo, Rocco; Bona, Roberta Della; Ricci, Davide; Canepa, Marco; Crimi, Gabriele; Santini, Francesco; Ameri, Pietro; Porto, Italo.
  • Benenati S; Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
  • Toma M; Department of Internal Medicine, University of Genoa, Genova, Italy.
  • Canale C; Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
  • Vergallo R; Department of Internal Medicine, University of Genoa, Genova, Italy.
  • Bona RD; Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
  • Ricci D; Department of Internal Medicine, University of Genoa, Genova, Italy.
  • Canepa M; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Crimi G; Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
  • Santini F; Cardiac Surgery Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
  • Ameri P; Department of Integrated Surgical and Diagnostic Sciences, University of Genova, Genova, Italy.
  • Porto I; Cardiovascular Disease Unit, IRCCS Policlinic Hospital San Martino, Genova, Italy.
Heart Fail Rev ; 27(3): 927-934, 2022 05.
Article en En | MEDLINE | ID: mdl-33677732
ABSTRACT
To compare the efficacy and safety of different mechanical circulatory support (MCS) devices in CS. A total of 24 studies (7 randomized controlled trials-RCTs-and 17 non-RCTs) involving 11,117 patients were entered in a Bayesian network meta-analysis. The primary endpoint was 30-day mortality. Secondary endpoints were stroke and bleeding (requiring transfusion and/or intracranial and/or fatal). Compared with no MCS, extra-corporeal membrane oxygenation (ECMO) reduced 30-day mortality when used both alone (OR 0.37, 95% CrI 0.15-0.90) and together with the micro-axial pump Impella (OR 0.13, 95% CrI 0.02-0.80) or intra-aortic balloon pump (IABP) (OR 0.19, 95% CrI 0.05-0.63), although the relevant articles were affected by significant publication bias. Consistent results were obtained in a sensitivity analysis including only studies of CS due to myocardial infarction. After halving the weight of studies with a non-RCT design, only the benefit of ECMO + IABP on 30-day mortality was maintained (OR 0.22, 95% CI 0.057-0.76). The risk of bleeding was increased by TandemHeart (OR 13, 95% CrI 3.50-59), Impella (OR 5, 95% CrI 1.60-18), and IABP (OR 2.2, 95% CrI 1.10-4.4). No significant differences were found across MCS strategies regarding stroke. Although limited by important quality issues, the studies performed so far indicate that ECMO, especially if combined with Impella or IABP, reduces short-term mortality in CS. MCS increases the hazard of bleeding.
Asunto(s)
Palabras clave

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Corazón Auxiliar / Accidente Cerebrovascular Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Corazón Auxiliar / Accidente Cerebrovascular Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article